News - BioPharm International

ADVERTISEMENT

News

Hospira's Australian Manufacturing Plant Receives FDA Warning Letter

October 3, 2014

Impurities, particulates, and a lack of communication are among Hospira's recent violations described in a warning letter from FDA.

Jagged Little Pill: Drug Delivery Through the Use of Microneedles

October 3, 2014

Delivery of large protein biopharmaceuticals may now be administered orally with the help of microneedles, according to researchers at MIT.

HydRIS Vaccine Stability Device Could Revolutionize Cold-Chain Requirements

October 2, 2014

Nova Bio-Pharma Technologies' new vaccine stability device eliminates the need for cold storage.

Making ZMapp: Production of Experimental Drug to Treat Ebola Is Now A Priority

October 2, 2014

Manufacturing drugs from biological sources sometimes can't be rushed, even when a rare disease becomes more widespread.

New Tax Rules May Deter Future Pharma M&A

October 1, 2014

Inversions in the pharmaceutical sector could become less lucrative as a result of new tax laws.

NIH Seeks to Improve Vaccine Response with New Adjuvants

September 30, 2014

NIH seeks new therapeutic products to bolster the protective properties of vaccines.

New Report Details Players and Pipelines in the Biosimilar Space

September 30, 2014

A new Thomson Reuters BioWorld report outlines the more than 700 biosimilars that are currently in development and the emerging business opportunities that exist in the biopharmaceutical space.

Baxter International Plans to Open R&D Center for Baxalta

September 30, 2014

Baxter International announced it will form a R&D center in Cambridge, Massachusetts for its new biopharmaceutical company, Baxalta.

FDA Releases First-Ever Purple Book for Biosimilar Characterization

September 26, 2014

The Purple Book will list biologic and biosimilar products and will serve as a guide for interchangeability.

ADVERTISEMENT

ADVERTISEMENT

Click here